Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New fat tissue injection passes first safety check in healthy volunteers

NCT ID NCT05518084

Knowledge-focused Sponsor: Linio Biotech Oy Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a new cell-free fat tissue product, called Liponovo, is safe to inject into the skin. 38 healthy adults received an injection of the product in one arm and a plain saltwater solution in the other. Researchers monitored for side effects like redness, swelling, or allergic reactions over time. The trial is complete, but it only looked at safety, not whether the product works for any medical condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Liponovo tissue product (a cell-free fat tissue product)
What this could lead to
If proven safe, this product could be developed for future medical uses, such as tissue repair or cosmetic procedures.
What could go wrong
This was a very early safety study in healthy people, not patients. It does not test if the product works for any disease. Side effects may still appear in later studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

38 people

The number who actually took part.

Started

Aug 2022

Finished

Feb 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult (age 18 years or more) * Healthy skin in the studied area (dorsal forearm, proximal third) * Able and willing to give informed consent * Reasonably accessible to the study clinic and compliant to follow-up visits Exclusion Criteria: * known allergy to any of the preparations used in the study (Liponovo tissue product and Ringer-Acetat) or earlier/known anaphylaxis reaction for any allergen * hematologic or other bleeding disorder * use of antitrombotic/ anticoagulation medicine * autoimmune disease * immunosupressive disease or medication * cancer or neoplastic disease * connective tissue disease * diabetes type 1 or 2 or other metabolic diseases * smoking * pregnancy or nursing * sunbathing during last 7 days * a skin disease that is or has been symptomatic in the studied area * test subjects with previous fat or hyaluronic acid filling under the same area * those who withhold consent * Use of following medications: * Histamine receptor-blockers \<7 days before study initiation * Topical corticosteroids in test area \<7 days before study initiation * Topical calsineurin inhibitors \<7days before study initiation * Longterm (\>10days before study initiation) systemic prednisolon \>10mg/d * Omalitsumabi \< 4weeks before study initiation * Doksepin \< 7 days before study initiation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Safety issues are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Safety issues

Contacts and locations

Locations

  • Terveystalo, Ruoholahti

    Helsinki, Finland

More trials for these conditions

Other studies related to the condition(s) this trial covers.